CD274 and non-small cell lung carcinoma: Monoclonal antibodies against programmed death 1 (PD1)/ programmed death-ligand 1 (PD-L1) were shown to possess remarkable antitumor activity against several cancers, including non-small cell lung cancer (NSCLC).